⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLR News
Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
globenewswire.com
ALLR
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
globenewswire.com
ALLR
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
globenewswire.com
ALLR